NASDAQ:GEMP Gemphire Therapeutics (GEMP) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free GEMP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.22▼$4.3850-Day Range$0.30▼$6.3852-Week Range$0.24▼$1.49Volume73,951 shsAverage Volume127,174 shsMarket Capitalization$63.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Gemphire Therapeutics alerts: Email Address Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About Gemphire Therapeutics Stock (NASDAQ:GEMP)Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here GEMP Stock News HeadlinesMay 11, 2023 | marketwatch.comHypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030April 28, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030March 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.April 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesMarch 29, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027March 26, 2023 | marketwatch.comGlobal Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReportsMarch 24, 2023 | marketwatch.com2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]March 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 2, 2023 | marketwatch.comHypertriglyceridemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029March 1, 2023 | marketwatch.comHypertriglyceridemia Treatment Market 2023 Growth, Trends With the Rise in ICT Industry 2029February 17, 2023 | marketwatch.comLatest Hypertriglyceridemia Treatment Market Research Report (2023-2028)-Key Takeaways from Top CompaniesFebruary 15, 2023 | marketwatch.comWorldwide Nonalcoholic Steatohepatitis (NASH) Market 2023 with Growth Analysis by Size and Share to 2027 | 99 PagesJanuary 24, 2023 | finance.yahoo.comBiVictriX Therapeutics makes 'fundamental step forward'April 6, 2022 | marketwatch.comHypertriglyceridemia Treatment Market Size 2022 Analysis Growth Report by Trends, Applications, Types, Competitive Strategies and Forecast to 2029March 31, 2022 | marketwatch.comGlobal Hypercholesterolemia Treatment Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028October 13, 2021 | markets.businessinsider.comNeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without ModificationSee More Headlines Receive GEMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GEMP CUSIPN/A CIK1638287 Webwww.gemphire.com Phone734-245-1700FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-419.70% Return on Assets-173.05% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book7.96Miscellaneous Outstanding Shares14,872,000Free FloatN/AMarket Cap$63.95 million OptionableNot Optionable Beta2.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Charles L. Bisgaier (Age 65)Co-Founder, Chairman & Chief Scientific Officer Dr. Steven R. Gullans (Age 66)CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer Mr. Seth Reno (Age 52)Chief Commercial Officer Mr. Jeffrey S. Mathiesen C.P.A. (Age 58)CPA, Consultant Ms. Amy Zaremba RabournDirector of Fin.Key CompetitorsKezar Life SciencesNASDAQ:KZREagle PharmaceuticalsNASDAQ:EGRXKorro BioNASDAQ:KRROAnebulo PharmaceuticalsNASDAQ:ANEBMediciNovaNASDAQ:MNOVView All Competitors GEMP Stock Analysis - Frequently Asked Questions How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) announced its earnings results on Friday, March, 15th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.15. What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Alexion Pharmaceuticals (ALXN), Clearside Biomedical (CLSD), Intel (INTC), Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT). When did Gemphire Therapeutics IPO? Gemphire Therapeutics (GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. This page (NASDAQ:GEMP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.